StockNews.com started coverage on shares of Arch Biopartners (NYSE:ARCH – Free Report) in a research note issued to investors on Sunday. The brokerage issued a hold rating on the stock.
Arch Biopartners Stock Performance
Shares of ARCH opened at $134.83 on Friday. Arch Biopartners has a 12-month low of $116.44 and a 12-month high of $180.65.
Institutional Trading of Arch Biopartners
A hedge fund recently bought a new stake in Arch Biopartners stock. Total Clarity Wealth Management Inc. bought a new stake in Arch Biopartners Inc. (NYSE:ARCH – Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 329 shares of the company’s stock, valued at approximately $47,000.
Featured Stories
- Five stocks we like better than Arch Biopartners
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Nextracker’s Solar Surge: Will It Shatter Its All-Time High?
- How Investors Can Find the Best Cheap Dividend Stocks
- Savvy Investors Are Raising a Glass for Heineken Stock
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Top 4 ETFs for China Exposure After Tariff Relief
Receive News & Ratings for Arch Biopartners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arch Biopartners and related companies with MarketBeat.com's FREE daily email newsletter.
